A randomized controlled trial of lamivudine to treat acute hepatitis B

Hepatology

Volumn 45, Issue 1, 2007, Pages 97-101

  Kumar, M ^a   Satapathy, S ^a   Monga, R ^a   Das, K ^a   Hissar, S ^a   Pande, C ^a   Sharma, B C ^a   Sarin, S K ^a  

^a G B PANT HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PLACEBO; VIRUS DNA;

ACUTE HEPATITIS; ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEMALE; FOLLOW UP; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOCOMPETENCE; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUROPATHY; PANCREATITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; BILIRUBIN; CHILD; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOCOMPETENCE; LAMIVUDINE; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 33846447769     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21486     Document Type: Article

References (14)

1. Yuki N, Nagaoka T, Yamashiro M, Mochizuki K, Kaneko A, Yamamoto K, et al. Long-term histologic and virologic outcomes of acute self-limited hepatitis B. HEPATOLOGY 2003;37:1172-1179.
2. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-1661.
3. Andreone P, Caraceni P, Grazi GL, Belli L, Milandri GL, Ercolani G, et al. Lamivudine treatment for acute hepatitis B after liver transplantation. J Hepatol 1998;29:985-989.
4. Castells L, Vargas V, Rodriguez F, Allende H, Buti M, Sanchez-AvilaJF, et al. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation. Liver Transpl 2002;8:892-900.
5. Reshef R, Sbait W, Tur-Kaspa R. Lamivudine in the treatment of acute hepatitis B. N Engl J Med 2000;343:1123-1124.
6. Torii N, Hasegawa K, Ogawa M, Hashino E, Hayashi N. Effectiveness and long-term outcome of lamivudine therapy for acute hepatitis B. Hepatol Res 2002;24:34.
7. Abagiu AO, Duna FM, Radulescu CA. Lamivudine in severe acute viral B hepatitis. J Hepatol 2003;38(Suppl):121.
8. Schmilovitz-Weiss H, Ben-Ari Z, Sikuler E, Zuckerman E, Sbeit W, Ackerman Z, et al. Lamivudine treatment for acute severe hepatitis B: a pilot study. Liver Int 2004;24:547-551.
9. Wakil SM, Kazim SN, Khan LA, Raisuddin S, Parvez MK, Guptan RC, et al. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus. J Med Virol 2002;68:311-318.
10. Kazim SN, Sarin SK, Sharma BC, Khan LA, Hasnain SE. Characterization of naturally occurring and Lamivudine-induced surface gene mutants of hepatitis B virus in patients with chronic hepatitis B in India. Intervirology 2006;49:152-160.
11. Atkins M, Hunt CM, Brown N, Gray F, Sanathanan L, Woessner M, et al. Clinical significance of YMDD mutant hepatitis B virus (HBV) in a large cohort of lamivudine-treated hepatitis B patients. HEPATOLOGY 1988;28:319A.
12. Saracco G, Macagno S, Rosina F, Rizzetto M. Serologic markers with fulminant hepatitis in persons positive for hepatitis B surface antigen. A worldwide epidemiologic and clinical survey. Ann Intern Med 1988;108:380-383.
13. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995;13:29-60.
14. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance widiout destruction of infected cells during acute HBV infection. Science 1999;284:825-829.